#### **Initial Case Quality Control Form**

Endometrial (UCEC)

**Instructions:** This form should be completed for all cases submitted for TCGA, prior to the shipment of samples to the BCR.

Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.

Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis

reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.								
Γissue	Source Site (TSS):	TSS ID: TSS Unique Patient ID: Interviewer Name:	Interview Date/ / /					
	as this TSS received permission from the NCI to provide time intervals as a substitute for requested dates on this form? $\Box$ Yes $\Box$ No ote: Provided time intervals must begin with the date of initial pathologic diagnosis.							
Tumo	or Information: The following	g sections are to be provided by a Pathologist						
#	Question	Entry Alternatives	Working Instructions					
1	Histologic Subtype of Tumor Submitted for TCGA	☐ Endometrioid endometrial adenocarcinoma ☐ Serous endometrial adenocarcinoma ☐ Mixed serous and endometrioid	Indicate the confirmed diagnosis of the tumor submitted for TCGA. 3081934					
2	Tumor Type	☐ Primary (primary untreated malignant biospecimen)	Indicate the type of tumor submitted for TCGA.  3288124  This is a biospecimen that has not been treated with chemotherapy or radiation prior to resection.					
3	Anatomic Organ Sub- Division of Frozen Biospecimen	☐ Endometrial cavity, NOS ☐ Lower uterine segment/ Isthmus uteri ☐ Fundus uteri ☐ Adenomyosis	Indicate the anatomic site of the frozen tumor biospecimen submitted for TCGA.  2008006					
Date	of Cancer Sample Procure	ment						
4	Month of Cancer Sample Procurement	□01 □02 □03 □04 □05 □06 □07 □08 □09 □10 □11 □12	Provide the month of the procedure performed to obtain the malignant tissue submitted for TCGA.  3008197					
5	Day of Cancer Sample Procurement	01       02       03       04       05       06       07       08       09       10       11       12         013       14       15       16       17       18       19       20       21       22       23       24         025       26       27       28       29       30       31	Provide the day of the procedure performed to obtain the malignant tissue submitted for TCGA. $\underline{3008195}$					
6	Year of Cancer Sample Procurement		Provide the year of the procedure performed to obtain the malignant tissue submitted for TCGA.  3008199					
7	Method of Cancer Sample Procurement	□ Surgical Resection □ Full Hysterectomy □ Endometrial Biopsy □ Partial Hysterectomy □ Endometrial curettage, NOS □ Hysterectomy, NOS □ Other Method (please specify)	Indicate the procedure performed to obtain the malignant tissue submitted for TCGA. $\underline{3103514}$					
8	Other Method of Cancer Sample Procurement		If the procedure performed to obtain the malignant tissue is not included in the provided list, specify the procedure. $\underline{2006730}$					
9	Country Where Cancer Sample was Procured		Provide the country where the tissue submitted for TCGA was procured. $\underline{3203072}$					

Page 2

#### Initial Case Quality Control Form

V4.03 091112

Endometrial (UCEC)

#	Question	Entry Alternatives	Working Instructions
10	Race	<ul> <li>□ American Indian or Alaska Native         <ul> <li>A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.</li> <li>□ Asian</li></ul></li></ul>	Provide the patient's race using the defined categories.  2192199
11	Ethnicity	<ul> <li>Not Hispanic or Latino         <ul> <li>A person not meeting the definition of Hispanic or Latino.</li> </ul> </li> <li>Hispanic or Latino             <ul> <li>A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race.</li> </ul> </li> <li>Not Evaluated         <ul> <li>Not provided or available.</li> <li>Unknown</li></ul></li></ul>	Provide the patient's ethnicity using the defined categories. 2192217
12	Vessel Used	☐ Cryovial ☐ Cassette ☐ Other, specify ☐ Biospecimen Storage Bag ☐ Cryomold	Indicate the type of vessel used to ship the tissue to the Biospecimen Core Resource (BCR) for TCGA.  3081940
13	Other Vessel Used		If the vessel used to ship the tissue to the BCR is not included in the provided list, specify the vessel used.  3288137
14	Is tumor sample being submitted for Laser Cryo-Enrichment (LCE)?	□ Yes □ No	Indicate whether the tumor sample submitted to the BCR is intended to undergo Laser Cryo-Enrichment (LCE) after the BCR receives the sample.  3288488
15	Was sample prescreened at site?	□ Yes □ No	Indicate whether the sample submitted to the BCR was prescreened at the TSS.  3081942
Tum	or Slides Submitted		
<u>16</u>	Types of Slides Submitted	□ Physical Top Slide □ Digital Top Slide Image □ Physical FFPE Slide □ Digital FFPE Slide Image	Indicate the type(s) of slide(s) submitted to the BCR.  TBD  Top Slide Definition: Slide cut directly from frozen biospecimen = mirror image of inked surface
<u>17</u>	Slide/Digital Image ID #		Provide the slide ID for each slide (physical and digital image) submitted to the BCR.  2321277

#	Question Entry Alternatives Working Instructions										
#	Question	Entry Aiternatives	Provide the TSS unique tumor ID. If multiple pieces of tumor								
<u>18</u>	Tumor Identifier		are submitted, each tumor needs a unique ID. 3288096								
<u>19</u>	Weight of Frozen Tumor	(mg)	Provide the weight of the tumor sample submitted for TCGA. 3081946  Weight can be estimated based on the size of the tumor submitted.								
20	Tumor Nuclei %	(%)	Provide the percent of tumor nuclei for the sample submitted for TCGA.  2841225 Check with the BCR to confirm the current acceptable TCGA metrics.								
21	Necrosis %	(%)	Provide the percent of necrosis for the sample submitted for TCGA.  2841237 Check with the BCR to confirm the current acceptable TCGA metrics.								
Norm	al Information A normal co	ontrol must be present to qualify.									
22	Type(s) of Normal Control Check all that apply	☐ Whole Blood ☐ Extracted DNA from Blood ☐ Buffy Coat ☐ Non-Neoplastic Control Tissue* ☐ Lymphocytes	Indicate the type of normal control submitted for this case. 3081936 *Non-neoplastic Control Tissue may only be submitted with NCI approval.								
Nori	nal Control: Whole Blood										
23	Method of Normal Sample Procurement	□ Blood Draw	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147								
24	Month of Normal Sample Procurement	01     02     03     04     05     06     07     08     09     10     11     12	Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195								
25	Day of Normal Sample Procurement	01       02       03       04       05       06       07       08       09       10       11       12         13       14       15       16       17       18       19       20       21       22       23       24         25       26       27       28       29       30       31	Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196								
26	Year of Normal Sample Procurement		Provide the year of the procedure performed to obtain the normal control submitted for TCGA.  3288197								
<u>27</u>	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138								
Norr	Normal Control: Buffy Coat/ Lymphocytes										
28	Normal Control Type	☐ Buffy Coat ☐ Lymphocytes	Indicate the type of normal control submitted for TCGA. $3081936$								
29	Method of Normal Sample Procurement	□ Blood Draw	Indicate the procedure performed to obtain the normal control sample submitted for TCGA.  3288147								
30	Month of Normal Sample Procurement	01     02     03     04     05     06     07     08     09     10     11     01	Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195								

# Initial Case Quality Control Form Endometrial (UCEC)

#	Question		Entry Alternatives											Working Instructions
31		□ 01 □ 13 □ 25	□ 02 □ 14 □ 26	□ 03 □ 15 □ 27	□ 04 □ 16 □ 28	□ 05 □ 17 □ 29	□ 06 □ 18 □ 30	□ 07 □ 19 □ 31	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196
32	Year of Normal Sample Procurement													Provide the year of the procedure performed to obtain the normal control submitted for TCGA.  3288197
33	Normal Identifier										Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138			
Norn	nal Control: Extracted DNA	from Bl	ood											
34	Method of Normal Sample Procurement	□ Bloo	od Drav	N										Indicate the procedure performed to obtain the normal control sample submitted for TCGA.  3288147
35	Month of Normal Sample Procurement	<b>1</b> 01	<b>1</b> 02	<b>1</b> 03	<b>1</b> 04	<b>1</b> 05	<b>1</b> 06	<b>1</b> 07	□ 08	<b>1</b> 09	<b>1</b> 0	<b>1</b> 11	<b>1</b> 2	Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195
36	Day of Normal Sample	□ 01 □ 13 □ 25	□ 02 □ 14 □ 26	□ 03 □ 15 □ 27	□ 04 □ 16 □ 28	□ 05 □ 17 □ 29	□ 06 □ 18 □ 30	□ 07 □ 19 □ 31	□ 08 □ 20	□ 09 □ 21	□ 10 □ 22	□ 11 □ 23	□ 12 □ 24	Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196
37	Year of Normal Sample Procurement													Provide the year of the procedure performed to obtain the normal control submitted for TCGA.  3288197
<u>38</u>	Normal Identifier													Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138
<u>39</u>	Extracted DNA Quantity		(μg)						Provide the quantity (µg) of the normal control sample sent to the BCR for TCGA. $\underline{3288185}$					
<u>40</u>	Extracted DNA Quantification Method							Provide the quantification method of the normal control sample sent to the BCR for TCGA. $\underline{3288186}$						
41	Extracted DNA Concentration		(μg/μL)				Provide the concentration (µg/ µL) of the normal control sample sent to the BCR for TCGA. $\underline{3288187}$							
<u>42</u>	Extracted DNA Volume								(μL)	1				Provide the volume ( $\mu L$ ) of the normal control sample sent to the BCR for TCGA. <u>3288188</u>
Norn	nal Control: Non-Neoplastic	Contro	l Tissu	е										
43	Method of Normal Sample Procurement			esection nod (ple		cify)								Indicate the procedure performed to obtain the normal control sample submitted for TCGA.  3288147
44	Other Method of Normal Sample Procurement													If the procedure performed to obtain the normal sample is not included in the provided list, specify the procedure. $\underline{3288151}$

# Initial Case Quality Control Form Endometrial (UCEC)

#	Question	Entry Alternatives	Working Instructions				
45	Month of Normal Sample Procurement		Provide the month of the procedure performed to obtain the normal control submitted for TCGA.  3288195				
46	Day of Normal Sample Procurement	01       02       03       04       05       06       07       08       09       10       11       12         13       14       15       16       17       18       19       20       21       22       23       24         25       26       27       28       29       30       31	Provide the day of the procedure performed to obtain the normal control submitted for TCGA.  3288196				
47	Year of Normal Sample Procurement		Provide the year of the procedure performed to obtain the normal control submitted for TCGA.  3288197				
<u>48</u>	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138				
49	Anatomic Site of Non- Neoplastic Control Tissue	□ Myometrium       □ Uterine Cervix - NOS         □ Omentum       □ Fallopian tube         □ Ovary       □ Other (please specify)	If the normal control type is normal tissue, indicate the anatomic site of the non-neoplastic control tissue submitted for TCGA.  3081938				
<u>50</u>	Other Site of Non- Neoplastic Control Tissue		If the normal control type is normal tissue and the anatomic site is not included in the provided list, specify the site of the non-neoplastic control. 3288189				
<u>51</u>	Proximity of Normal Tissue to Tumor	☐ Distal (> 2cm) from the primary tumor	If the normal control type is normal tissue, confirm that the submitted normal tissue was at least 2cm away from the primary tumor.  3088708  Adjacent (≤ 2cm) Normal Tissue is not accepted for this tissue type. Unknown Normal Tissue is not acceptable for this tissue type.				
<u>52</u>	Normal Slide ID#		If the normal control type is normal tissue, provide the slide ID for the physical top slide OR the digital slide image of the normal control being sent to the BCR.  3288217				
<b>Verification:</b> By providing the below information, the Principal Investigator acknowledges that the information provided by the institution is true and correct and has been quality controlled.							
Tissu repoi	Pathology Review Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.						
53	Name of Pathologist		Provide the name of the Pathologist that provided the information for all previous sections.  3288225				
54	Date of Pathologist Review		Provide the date of the pathology review performed by the TSS pathologist above.  3288224				
Prin	cipal Investigator/Authori	zed Designee Confirmation					
55	Percent Tumor Nuclei meets TCGA metrics?	□ Yes □ No	Confirm that the malignant sample submitted to the BCR meets the current tumor nuclei metrics for TCGA.  3288520 Check with the BCR to confirm the current acceptable TCGA metrics.				
	-						

Page 6

# Initial Case Quality Control Form Endometrial (UCEC)

V4.03 091112

#	Question	Entry Alternatives	Working Instructions
56	Percent Necrosis meets TCGA metrics?	□ Yes □ No	Confirm that the malignant sample submitted to the BCR meets the current necrosis metrics for TCGA.  3288524 Check with the BCR to confirm the current acceptable TCGA metrics.
57	De-Identified Pathology Report Submitted?	□ Yes □ No	Confirm that a de-identified pathology report will be sent to BCR prior to or with the shipment of the physical samples. 3288292
58	Is the histologic diagnosis on the CQCF (as determined by the TSS pathology review of the TCGA frozen section top slide) consistent with the histology listed in the final diagnosis on the pathology report?	□ Yes □ No	Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted to TCGA is consistent with the diagnosis found on the patient's pathology report for the tumor being sent to the BCR.  3288300  If "yes," skip related question below.  The diagnosis is considered to be consistent if at least one of the following criteria are met:  1) Diagnosis on the CQCF is identical to the pathology report for the tumor being sent to the BCR.  2) Diagnosis on the CQCF includes as least one of the subtypes listed on the pathology report and all subtypes on the pathology report are acceptable for TCGA.  3) Diagnosis on the CQCF is "histology, NOS" (i.e., Adenocarcinoma, NOS) and the pathology report lists a specific subtype within the same histologic group  4) Diagnosis on the CQCF indicates "Mixed Subtype" and the pathology report lists two or more acceptable subtypes, provided that percent subtype(s) meet applicable TCGA disease-specific requirements.
59	If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency.	<ul> <li>□ Macrodissection performed at TSS to select for a region containing an acceptable TCGA diagnosis (see note at right)</li> <li>□ Pathology analysis at TSS determined a specific histological subtype different from original pathology report (see note at right)</li> <li>□ Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right)</li> </ul>	If the diagnosis provided on this form is not consistent with the diagnosis found on the pathology report provided, specify a reason for this inconsistency.  3288315  If a TSS pathology review of the TCGA committed sample resulted in a different histological subtype than what is documented on the original pathology report, an amendment to the pathology report should be submitted when the sample is shipped to the BCR; or in the absence of an amended pathology report, the TSS must complete and submit an electronic copy of the "TCGA Pathologic Diagnosis Discrepancy Form". In the case of diagnosis modifications, institution protocol should be followed for proper quality assurance.
60	History of Other Malignancy	□ None □ History of Prior Malignancy □ History of Synchronous/ Bilateral Malignancy □ Both History of Synchronous/ Bilateral and Prior Malignancy	Indicate whether the patient has a history of malignancies. If the patient has any history, including synchronous or bilateral malignancies, please complete an "Other Malignancy Form" for each malignancy diagnosed prior to the procurement of the tissue submitted for TCGA.  3382736  If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, complete an OMF for the first diagnosis for each of these types.

Page 7

### **Initial Case Quality Control Form**

171.	03	091	11	12
V T.	$U_{\mathcal{O}}$	ひシュ	LL	14

Endometrial (UCEC)

#	Question	Entry Alternatives	Working Instructions
61	History of Neoadjuvant Treatment <i>for Tumor</i> <i>Submitted for TCGA</i>	□ None □ Radiation prior to sample procurement* □ Pharmaceutical treatment prior to sample procurement* □ Both pharmaceutical treatment and radiation prior to sample procurement*	Indicate whether the patient received therapy for this cancer prior to the sample procurement of <b>the tumor submitted for TCGA</b> . If the patient did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instruction.  3382737  *Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to the procurement of the sample submitted for TCGA are exclusionary.
62	Consent Status	☐ Consented ☐ Exemption 4* ☐ Deceased ☐ Waiver*	Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent. 3288361  *Exemptions and waivers for consent must be approved by NCI.
Date	of Consent		
63	Month of Consent	□ 01 □ 02 □ 03 □ 04 □ 05 □ 06 □ 07 □ 08 □ 09 □ 10 □ 11 □ 12	If the patient was formally consented, provide the month of consent. $\underline{3081955}$
64	Day of Consent	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	If the patient was formally consented, provide the day of consent. $\underline{3081957}$
65	Year of Consent		If the patient was formally consented, provide the year of consent. $\underline{3081959}$
Date	of Death Do not complete da	te of death, if patient formally consented.	
66	Month of Death	□ 01 □ 02 □ 03 □ 04 □ 05 □ 06 □ 07 □ 08 □ 09 □ 10 □ 11 □ 12	If the patient consented by death, provide the month of death. $\underline{2897026}$
67	Day of Death	01       02       03       04       05       06       07       08       09       10       11       12         13       14       15       16       17       18       19       20       21       22       23       24         25       26       27       28       29       30       31	If the patient consented by death, provide the day of death. 2897028
68	Year of Death		If the patient consented by death, provide the year of death. 2897030
			_//

Print Name

Date

Principal Investigator or Designee Signature

#### Initial Case Quality Control Form

V4.03 091112

Endometrial (UCEC)

**Time Intervals:** The following questions are only to be answered if the Tissue Source Site is unable to provide the dates requested on this form.

#	Question	Entry Alternatives	Working Instructions
ii	Number of Days from Date of Diagnosis to Date of Cancer Sample Procurement	days	Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the procedure that produced the malignant sample submitted for TCGA.  3288495
iii	Number of Days from Date of Diagnosis to Normal Sample Procurement	days	Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the procedure that produced the normal control sample submitted for TCGA.  3288496
iv	Number of Days from Date of Diagnosis to Date of Pathological Review	days	Provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the pathological review performed as part of the submission process for TCGA.  3288497
v	Number of Days from Date of Diagnosis to Date of Consent	days	If the patient formally consented, provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the patient's formal consent.  3288498
vi	Number of Days from Date of Diagnosis to Date of Death	days	If the patient consented by death, provide the number of days from the date the patient was diagnosed with the disease described on this form to the date of the patient's death. 3288499  Do not complete days to death, if patient formally consented.